Amber Salzman and Dan Hart (Epic Bio)

Big Phar­ma vet teams with for­mer Doud­na pupil to launch new epigenome start­up

A for­mer doc­tor­al can­di­date in CRISPR pi­o­neer Jen­nifer Doud­na’s lab found­ed a new biotech seek­ing to wade in­to “epi­ge­net­ics-lev­el gene edit­ing,” and has now se­cured enough cap­i­tal to do just that.

The new San Fran­cis­co start­up, Epic Bio, put out word ear­ly Tues­day that it had of­fi­cial­ly launched, se­cur­ing a Se­ries A worth $55 mil­lion. That should be enough to fund the biotech’s dash to­wards the clin­ic, and CEO Am­ber Salz­man tells End­points News the goal is to reach it by the end of next year.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.